GRACE :: Lung Cancer

Stage IIIA

Denise Brock

Lung Cancer Video Library – Spanish Language: Video #42 Stage IIIA N2 Non-Small Cell Lung Cancer

Share
 
GRACE Cancer Video Library - Lung

 

We are pleased to continue this series of informational videos for our Spanish speaking community.  GRACE is pleased to welcome Dr. Rafael Santana-Davila, Assistant Professor with the University of Washington School of Medicine and Seattle Cancer Care Alliance.  In this 42nd video for the Spanish lung cancer video library, Dr. Santana-Davila joined GRACE to discuss Stage IIIA N2 Non-Small Cell Lung Cancer.


 

 

 

How Did You Like This Video?

Please feel free to offer comments and raise questions in our Discussion Forums.


 

TRANSCRIPTS – Spanish and English
download transcripts
 

Tratamiento del Paciente que Tiene Estadio Tres, cuando los Ganglios del Mismo Lado del Mediastino están Involucrados

Stage IIIA N2 Non-Small Cell Lung Cancer

 

Rafael Santana-Davila, MD
Assistant Professor of Medicine
University of Washington Seattle Cancer Care Alliance
Seattle, Washington

 

Spanish TRANSCRIPT

Cuando esto ocurre, el tratamiento varía mucho dependiendo de la institución que este viendo al paciente. En la Universidad de Washington lo que hacemos es que si hay un solo ganglio linfático involucrado preferimos dar quimioterapia. En un principio de 3 a 4 ciclos, después repetimos los estudios de imágenes y si el cancer no ha avanzado se lleva al paciente a cirugía donde lo primero que se hace es ver cuáles de los ganglios del mediastino están involucrados. Si el cancer no ha avanzado, se trata posteriormente con una lobectomía (remover el lóbulo del pulmón). Después, si los ganglios del mediastino se vieron afectados, entonces el paciente se hace candidato para ser tratado con radioterapia para erradicar esos ganglios del mediastino.

Cuando el cancer de pulmón está en más de un ganglio en el mediastino, lo que hacemos es quimioterapia y radiación al mismo tiempo. Son de cuatro a seis semanas de radiación con quimioterapia, dependiendo de que quimioterapia se elige, se puede dar una por semana o dar dos ciclos de quimioterapia en toda la radiación. La quimioterapia que se escoge depende mucho de la discusión entre doctor y paciente para ver qué efectos adversos se prefieren y cuáles son los riesgos y beneficios. 


  

English TRANSCRIPT

When the patient is in stage three, there are many options for the treatment depending on the institution the patient is being treated. In the University of Washington, if there is only one lymph node affected, we prefer to give chemotherapy. At first, we’ll give three to four cycles then we’ll do again imaging studies to see if the cancer has not spread. If the cancer has advanced to other parts, the patient will go into surgery to see which lymph nodes from the mediastinum are involved. However, if the cancer has not spread, the procedure used will be a lobectomy (remove one of the lobes of the lung).  Then, if the lymph nodes of the mediastinum are affected, the patient will be candidate to be treated with radiotherapy. 

When the lung cancer is in more lymph nodes in the mediastinum, we’ll then use chemotherapy and radiation at the same time. This consists of four to six weeks of radiation and chemotherapy. Depending on the type of chemotherapy selected, the treatment could be one cycle per week or two chemotherapy cycles in all the radiation process. The type of chemotherapy selected depends on the doctor-patient discussion about the side effects, risks and benefits.


GRACE Video

Management of Locally Advanced NSCLC in the Elderly and Frail

Share
GRACE Cancer Video Library - Lung

GCVL_LU-EA02_Mark_Socinski_WCLC_6

 

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes strategies for treatment of the elderly and frail patient with locally advanced NSCLC.

Download Transcript

How Did You Like This Video?

Please feel free to offer comments and raise questions in our Discussion Forums.

 

Transcript

A substantial portion of our patients are over the age of 70, and this disease is still often associated with smoking, so the older patients tend to have more comorbidities, and often may have a frailness to them at the time of diagnosis. All the paradigms that we’ve been talking about — chemoradiation, surgical excision, certainly have a toxicity associated with them, and surgery has a risk of morbidity and mortality associated with it. So I think special consideration needs to be made to those elderly, frail patients which have been largely underrepresented in many clinical trials because they would have been excluded based on comorbidities or performance status, and therefore you can’t necessarily apply the paradigms defined in published clinical trials to this population.

It is very clear that, for instance, in the chemoradiation world, the standard of care is concurrent use of chemoradiation. This substantially increases the risk of certain toxicities such as esophagitis, myelosuppression, and fatigue, and may be very debilitating in an elderly, frail patient. So one must consider: is this the best treatment for that particular patient? In many patients, we may give a brief course, two to three cycles, of chemotherapy to see how they tolerate it, and then consider following it if they tolerate it well, and if they have a response, particularly with radiotherapy. Often we give that radiotherapy alone, or sometimes we give it with a low dose of chemotherapy during the radiation with a regimen such as carboplatinum and paclitaxel.

So that’s a very common approach at our institution. Alternatively, patients may start with concurrent radiotherapy, or we may start some frail patients who may have very symptomatic disease, who may have impending obstruction of a bronchus or something like that in the medial part of the chest — often we may start them with radiotherapy alone with the intent to palliate their symptoms, to relieve the obstruction as best we can, and then again, if patents do well with initial radiotherapy, follow it up with systemic therapy following this — assuming that the patient’s condition improves as a result of the initial radiotherapy.

So, I don’t know in this population of elderly, frail patients that there’s a one size that fits all. I think one has to review the CT scans, examine the patient, get an idea of how symptomatic the patient is and what the symptoms are. I do think the strategy of chemotherapy alone, followed by radiation, or sequential strategy is something that we do quite often in this population. I think that concurrent chemoradiotherapy can be done with low dose strategies in an eldery, frail population, and actually may be a reasonable strategy if you have local/regional issues that need attention, such as impending bronchial obstruction would be the best example there. We do know that adding chemotherapy to radiation does lead to better regional control in the area, or the field of radiation. So again, I think one has to personalize and customize the treatment for this elderly, frail population.


GRACE Video

Defining Resectability in Stage IIIA Lung Cancer

Share
GRACE Cancer Video Library - Lung

GCVL_LU-E05_Mark_Socinski_WCLC_5

 

Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the factors to consider in defining resectability in stage IIIa lung cancer.

[]

Download Transcript

How Did You Like This Video?

Please feel free to offer comments and raise questions in our Discussion Forums.

 

Transcript

Defining resectability in stage III lung cancer really needs to be under the supervision of a qualified thoracic surgeon. Ultimately, I say that no one but a surgeon should make the distinction of whether a patient is resectable or unresectable. Medical oncologists shouldn’t do it, pulmonologists shouldn’t do it, and radiation oncologists shouldn’t do it. These are specialties that are often involved, but really, the surgeon is the ultimate decision maker.  Now, obviously we can collaborate and discuss issues with regard to resectability with the surgeon, but I think ultimately, it comes down to that decision making process.

Now, obviously, resectability has to focus around two things — can you remove the primary tumor, and as we previously mentioned, T3 lesions that involve the pericardium, the diaphragm, the chest wall — these can typically be resected en bloc, taking part of the chest wall or part of the pericardium. I think that for experienced thoracic surgeons, that is not a difficult procedure. I think there are many questions when you start to have T4 lesions that involve vital structures such as the esophagus, the trachea, the great vessels, perhaps the spinal column, bony disease in that area — there are highly selected situations in which one may consider that with obviously, reconstruction of the vital structures. But, these are very few and far between, they need to be done by very experienced surgeons and a team of medical oncology and radiation oncology before I would embark on that sort of decision. T3 is a little bit easier than T4.

The second issue, and more common issue, is with regard to the mediastinal lymph nodes. Now obviously, if you have bilateral mediastinal involvement, and this would be both N2 and N3 — N2 being in the same side as the cancer, N3 being on the opposite side of the cancer, then we would say that patient is not resectable. N3, by definition, should preclude surgery and really is treated optimally with chemoradiation. The real issue centers down to those patients who have isolated N2 disease.

Now, there’s not universal agreement about what’s resectable and what’s not resectable. Certainly, if you have small lymph nodes measuring less than 2cm, and particularly if it’s only in one site, I think most people would consider those patients potentially resectable. The question starts to evolve when one gets into a situation of what we refer to as bulky lymph node involvement. Bulky is a bit of a random definition, most of us use over 2-3cm, and if you have that bulk, as particularly in multiple nodal stations, besides the trachea or the subcarinal area. I think with most of those patients, the likelihood that surgery is going to be able to completely sterilize the mediastinum is quite low, and I would consider that those patients would not be resectable, in that they should be best served by the combination of chemoradiotherapy, which still offers patients a chance at being cured, and as I have previously mentioned, it’s not clear in this population that surgery improves the overall cure rate of this subset of patients.

So I think, really in the non-bulky, particularly isolated, one-site lymph node involvement — that would be a patient that we may consider for preoperative treatment, either chemotherapy or chemoradiation as we talked about before; those would be considered potentially resectable patients.


GRACE Video

Neoadjuvant Chemotherapy vs. Chemo/Radiation for Stage IIIA NSCLC

Share
GRACE Cancer Video Library - Lung

GCVL_LU-E04_Mark_Socinski_WCLC_4

 

Dr. Mark Socinski, University of Pittsburgh Medical Center, compares the use of chemotherapy to chemo/radiation in the preoperative setting in stage IIIA lung cancer.

[]

Download Transcript

How Did You Like This Video?

Please feel free to offer comments and raise questions in our Discussion Forums.

 

Transcript

As I previously mentioned, the role of surgery in stage IIIA disease remains controversial, although there are many patents who are suitable candidates for this, and for whom this approach is a very reasonable approach. One of the questions that is often raised in this situation is: what type of treatment should the patient receive prior to going into the operating room? As I previously mentioned, if you document N2 disease, and in this case IIIA disease, going to the operating room should not be the initial therapeutic approach in these patients, and we generally believe that they need preoperative therapy. The two choices are chemotherapy alone, versus chemoradiation.

We actually have no good data to guide us in this way — both approaches seem to be reasonable, both approaches are backed by previous trials addressing these sorts of things. One of the issues with regard to chemoradiation is that one has to be careful about the dose in the field of radiation, as well as the timing of surgery, following this to avoid postoperative complications that can be difficult to manage in the postoperative setting.

Obviously with chemotherapy alone, you don’t have the risks of radiotherapy. There is some evidence to suggest that, perhaps, chemoradiation may improve local/regional control relative to chemotherapy; it may increase the rate of what we call downstaging, which we think is a positive prognostic thing. What I mean by downstaging is, if you know the lymph nodes are positive at the time of initial diagnosis, if you employ chemotherapy or chemoradiation at the time of surgical resection, those lymph nodes that were positive pretreatment are now negative, so the chemotherapy and chemoradiation had an effect. We tend to see higher downstaging rates with chemoradiation, and downstaging has been associated with improved survival in this population, so that might argue for preoperative chemoradiation as a more reasonable strategy, but the data is not entirely clear in this regard.

One thing I will say is that, whether it’s preoperative chemotherapy, or preoperative chemo/radiotherapy, the surgeon involved should be involved right from the beginning. He or she should be an experienced surgeon that does this quite often, so they know how to manage patients both prior to the operation, intraoperatively, as well as postoperatively to minimize the risk of some of the complications such as ARDS, volume overload, postoperative infections and arrhythmias, and those sorts of things really should be managed in experienced hands from the thoracic surgeon point of view.


GRACE Video

Overall Management for Stage IIIA Disease

Share
GRACE Cancer Video Library - Lung

GCVL_LU-E03_Mark_Socinski_WCLC_3

 

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the primary treatment options for stage IIIA NSCLC, including chemoradiation and surgery, and discusses trial evidence for each approach.

[]

Download Transcript

How Did You Like This Video?

Please feel free to offer comments and raise questions in our Discussion Forums.

 

Transcript

The overall management for stage IIIA disease really boils down to essentially two different strategies. One is chemoradiation, and the second is a surgical approach in which you would either use chemotherapy or chemoradiation prior to surgery, and maybe in some cases, following surgery. There is not an agreed-upon standard in this regard — we’ve had several trials looking at the role of surgery in stage IIIA disease, specifically in those patients who have N2, or lymph nodes that are positive on the same side of the tumor that reside in the mediastinum.

From these two experiences, one of which employed preoperative chemoradiation, the other employed preoperative chemotherapy alone, this surgical arm, relative to the radiotherapy arm, did not show a long-term survival advantage as a result of surgery. So surgery remains controversial in this setting — not to say that there are not selected patients in which surgery should be considered, but I think they have to be very highly selected in this particular setting.

Now, getting back to one of the points we discussed earlier — that’s the heterogeneity of the disease. Often, we’ll find that patients undergo preoperative staging, which is very important. One must define the pathologic contents of the mediastinal lymph nodes prior to deciding about taking that patient to the operating room. I would say that if you can document N2, or certainly N3 disease, that the initial maneuver should not be surgical resection of that patient. However, there are patients in whom preoperative assessment of the mediastinal lymph nodes does not detect mediastinal disease, but while in the operating room at the time of resection, microscopic N2 disease or unsuspected N2 disease is found.
I think most surgeons, if possible, if they could do a complete resection, and resect all the involved lymph nodes, I would agree that would be the right thing to do, and in that case I think there is a clear role for postoperative adjuvant chemotherapy in resected N2 disease, in consideration of postoperative radiotherapy, depending upon the nature and the extent of the N2 disease.


Ask Us, Q&A
Lung/Thoracic Cancer Expert Content

Archives

Share

GRACE Cancer Video Library - Lung Cancer Videos

 

2015_Immunotherapy_Forum_Videos

 

2015 Acquired Resistance in Lung Cancer Patient Forum Videos

Share

Join the GRACE Faculty

Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog
Share

Subscribe to the GRACEcast Podcast on iTunes

Share

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Other Resources

Share

ClinicalTrials.gov


Biomedical Learning Institute

peerview_institute_logo_243